Your browser doesn't support javascript.
loading
Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease.
Bakris, George; Chen, Cindy; Campbell, Alicia K; Ashton, Veronica; Haskell, Lloyd; Singhal, Mukul.
Afiliación
  • Bakris G; University of Chicago Medicine, Chicago, Illinois, USA.
  • Chen C; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
  • Campbell AK; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
  • Ashton V; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
  • Haskell L; Janssen Research & Development, LLC, Raritan, New Jersey, USA.
  • Singhal M; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
Am J Hypertens ; 37(6): 438-446, 2024 May 15.
Article en En | MEDLINE | ID: mdl-38436491
ABSTRACT

BACKGROUND:

Chronic kidney disease (CKD) is a common comorbidity in patients with apparent treatment-resistant hypertension (aTRH). We assessed clinical outcomes, healthcare resource utilization events, and costs in patients with aTRH or difficult-to-control hypertension and stage 3-4 CKD with uncontrolled vs. controlled BP.

METHODS:

This retrospective cohort study used linked IQVIA Ambulatory EMR-US and IQVIA PharMetrics Plus claims databases. Adult patients had claims for ≥3 antihypertensive medication classes within 30 days between 01/01/2015 and 06/30/2021, 2 office BP measures recorded 1-90 days apart, ≥1 claim with ICD-9/10-CM diagnosis codes for CKD 3/4, and ≥1 year of continuous enrollment. Baseline BP was defined as uncontrolled (≥130/80 mm Hg) or controlled (<130/80 mm Hg) BP. Outcomes included risk of major adverse cardiovascular events plus (MACE+; stroke, myocardial infarction, heart failure hospitalization), end-stage renal disease (ESRD), healthcare resource utilization events, and costs during follow-up.

RESULTS:

Of 3,966 patients with stage 3-4 CKD using ≥3 antihypertensive medications, 2,479 had uncontrolled BP and 1,487 had controlled BP. After adjusting for baseline differences, patients with uncontrolled vs. controlled BP had a higher risk of MACE+ (HR [95% CI] 1.18 [1.03-1.36]), ESRD (1.85 [1.44-2.39]), inpatient hospitalization (rate ratio [95% CI] 1.35 [1.28-1.43]), and outpatient visits (1.12 [1.11-1.12]) and incurred higher total medical and pharmacy costs (mean difference [95% CI] $10,055 [$6,741-$13,646] per patient per year).

CONCLUSIONS:

Patients with aTRH and stage 3-4 CKD and uncontrolled BP despite treatment with ≥3 antihypertensive classes had an increased risk of MACE+ and ESRD and incurred greater healthcare resource utilization and medical expenditures compared with patients taking ≥3 antihypertensive classes with controlled BP.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Presión Sanguínea / Resistencia a Medicamentos / Insuficiencia Renal Crónica / Hipertensión / Antihipertensivos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hypertens Asunto de la revista: ANGIOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Presión Sanguínea / Resistencia a Medicamentos / Insuficiencia Renal Crónica / Hipertensión / Antihipertensivos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hypertens Asunto de la revista: ANGIOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos